The European Hematology Association (EHA) Announces a New Era of Partnership with Interplan as its New Core PCO

The European Hematology Association (EHA) is delighted to announce to the conference and meeting community the outcome of its Core PCO Invitation To Tender (ITT).

EHA Statement on COVID-19 Vaccines

EHA-SHRC Hematology Tutorial on Thalassemia

Dates: May 10-11, 2018
Location: Shiraz, Iran
Chairs: M Karimi, MD Cappellini & A Taher

  

EHA in close collaboration with Shiraz Hematology Research Center and the Shiraz Medical Center, endorsed by the Iranian Pediatric Hematology Oncology Society, organize a two day tutorial on “Thalassemia”.…

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

New HemaSphere publication on IVDR implementation

The In Vitro Diagnostic medical devices Regulation (IVDR), which came in to force in May 2022 with the objective of safeguarding the quality and safety of diagnostic tests in the EU, has a major impact on commercially available IVDs (CEIVDs) and…

Shining a Light on Blood Cancer

EHA Launches Digital Campaign

In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

EHA undersigns Manifesto on Treatment Optimization

EHA has given its formal endorsement to the “Manifesto for a new approach for better medicine in Europe: Establishing Treatment Optimization as part of personalized medicine development”.